Stopping Cancer Before It Starts

Antiva is developing novel topical therapies to treat pre-cancerous lesions caused by HPV. Our passionate, experienced team is dedicated to improving health outcomes and access to care worldwide. We aim to empower patients with safe, effective treatment options, address health care disparities in underserved communities, and save lives globally. Our non-surgical treatment approach offers a simple and convenient alternative to stop HPV and precancerous lesions before they become cancer.

Antiva in the
News

April 21, 2021

Antiva Biosciences Appoints Clifford Samuel to Board of Directors Read more

August 16, 2018

A Women’s Health Startup Tried to Drum Up Interest for a Much-Needed Drug. Many Men Didn’t Get It Read article (pdf)

July 10, 2018

Antiva Biosciences Closes $15 Million Series C-1 Financing Read more